Quick Answer
Relay Therapeutics, Inc. reported Total Revenue of $15.36 million for fiscal year 2025.
Relay Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $15.36M +53.4% |
$10.01M -60.8% |
$25.55M +1749.8% |
$1.38M -54.4% |
$3.03M -96.3% |
$82.65M |
| Revenue (ASC 606) | $15.36M +53.4% |
$10.01M -60.8% |
$25.55M +1749.8% |
$1.38M -54.4% |
$3.03M -96.3% |
$82.65M |
| Net Income | -$276.48M +18.1% |
-$337.71M +1.2% |
-$341.97M -17.7% |
-$290.51M +20.2% |
-$363.87M -594.3% |
-$52.41M +30.4% |
| Diluted EPS | -$1.61 +31.8% |
-$2.36 +15.4% |
-$2.79 -7.7% |
-$2.59 +32.2% |
-$3.82 +29.3% |
-$5.40 |
| Total Assets | $621.33M -28.7% |
$871.30M +3.2% |
$843.98M -23.3% |
$1.10B +9.1% |
$1.01B +26.1% |
$799.83M +103.5% |
| Cash and Equivalents | $84.02M -32.4% |
$124.29M -13.5% |
$143.74M -5.3% |
$151.79M -45.8% |
$280.12M -37.4% |
$447.65M +967.0% |
| Stockholders Equity | $567.06M -27.1% |
$777.79M +3.4% |
$752.00M -20.9% |
$950.22M +5.8% |
$897.81M +17.6% |
$763.29M +523.0% |
| R&D Expense | — | — | — | — | — | $99.86M +42.0% |
| Operating Income | -$302.74M +18.7% |
-$372.47M +0.1% |
-$373.00M -24.6% |
-$299.27M +17.9% |
-$364.70M -553.6% |
-$55.80M +33.6% |
| Shares Outstanding | 173.87M +3.6% |
167.76M +31.6% |
127.46M +5.2% |
121.11M +11.9% |
108.21M +20.4% |
89.91M +2126.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | — | -100.0% |
| Revenue (ASC 606) | September 30, 2025 | $0.00 | — | -100.0% |
| Net Income | September 30, 2025 | -$74.15M | +15.8% | -5.4% |
| Diluted EPS | September 30, 2025 | -$0.43 | +31.7% | -4.9% |
| Total Assets | September 30, 2025 | $670.00M | -28.0% | -8.1% |
| Cash and Equivalents | September 30, 2025 | $91.56M | -39.9% | -19.6% |
| Stockholders Equity | September 30, 2025 | $607.71M | -27.6% | -8.7% |
| R&D Expense | March 31, 2021 | $30.62M | +41.1% | +25.6% |
| Operating Income | September 30, 2025 | -$80.39M | +16.6% | -4.6% |
| Shares Outstanding | September 30, 2025 | 172.63M | +3.4% | +0.5% |
- Relay Therapeutics, Inc. reported Total Revenue of $15.36 million for fiscal year 2025.
- Relay Therapeutics, Inc. showed an increase of +53.4% in Total Revenue compared to the prior fiscal year.
- Relay Therapeutics, Inc. reported Revenue (ASC 606) of $15.36 million for fiscal year 2025.
- Relay Therapeutics, Inc. showed an increase of +53.4% in Revenue (ASC 606) compared to the prior fiscal year.
- Relay Therapeutics, Inc. reported Net Income of -$276.48 million for fiscal year 2025.
- Relay Therapeutics, Inc. showed an increase of +18.1% in Net Income compared to the prior fiscal year.
- Relay Therapeutics, Inc. reported Diluted EPS of $1.61 per share (loss) for fiscal year 2025.
- Relay Therapeutics, Inc. showed an increase of +31.8% in Diluted EPS compared to the prior fiscal year.
- Relay Therapeutics, Inc. reported Total Assets of $621.33 million for fiscal year 2025.
- Relay Therapeutics, Inc. showed a decrease of -28.7% in Total Assets compared to the prior fiscal year.
- Relay Therapeutics, Inc. reported Cash and Equivalents of $84.02 million for fiscal year 2025.
- Relay Therapeutics, Inc. showed a decrease of -32.4% in Cash and Equivalents compared to the prior fiscal year.
- Relay Therapeutics, Inc. reported Stockholders Equity of $567.06 million for fiscal year 2025.
- Relay Therapeutics, Inc. showed a decrease of -27.1% in Stockholders Equity compared to the prior fiscal year.
- Relay Therapeutics, Inc. reported R&D Expense of $99.86 million for fiscal year 2020.
- Relay Therapeutics, Inc. showed an increase of +42.0% in R&D Expense compared to the prior fiscal year.
- Relay Therapeutics, Inc. reported Operating Income of -$302.74 million for fiscal year 2025.
- Relay Therapeutics, Inc. showed an increase of +18.7% in Operating Income compared to the prior fiscal year.
- Relay Therapeutics, Inc. reported Shares Outstanding of 173.87 million shares for fiscal year 2025.
- Relay Therapeutics, Inc. showed an increase of +3.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: